ConsumerAffairs

Faulty diabetes devices prompt urgent alert from FDA

A newly issued alert links certain FreeStyle Libre 3 and 3 Plus glucose-monitoring sensors to at least seven deaths and hundreds of serious injuries.
Seeking Alpha

Insulet Announces Omnipod® 5 System is Now Compatible with Abbott’s FreeStyle Libre 2 Plus Sensor in the U.S.

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the ...

FDA issues alert for faulty glucose monitors linked to 7 deaths: List of brands

The issue affected about 3 million Libre 3 and Libre 3 Plus sensors in the U.S. and globally Abbott has received reports of 736 serious health problems (57 in the U.S.) and seven deaths (none in the U ...
Nasdaq

Tandem Diabetes Care’s t:slim X2™ Insulin Pump is the First Automated Insulin Delivery System to Integrate with Abbott’s New FreeStyle Libre® 2 Plus Sensor

Abbott’s latest innovation, the FreeStyle Libre® 2 Plus sensor, is available for the first time for t:slim X2™ insulin pump users in the U.S. Tandem’s Control-IQ™ hybrid closed-loop technology now ...
Diabetes.co.uk

FreeStyle Libre: safety notice issued as injuries linked to malfunctioning glucose monitors

A subset of FreeStyle Libre 3 and Libre 3 Plus sensors can give falsely low glucose readings, with 736 serious adverse events and seven deaths reported worldwide. Only specific Libre 3 and Libre 3 ...

Seven deaths linked to malfunctioning glucose monitors

Some FreeStyle Libre 3 glucose sensors made by Abbott Diabetes Care may give incorrect low readings. The devices have been ...
Nasdaq

Abbott's FreeStyle® Libre 3 System Receives CE Mark - Features World's Smallest, Thinnest Sensor with Best-in-Class Performance at the Same Low Cost for People with Diabetes

- The FreeStyle Libre 3 system automatically delivers real-time, up-to-the-minute glucose readings, unsurpassed 14-day accuracy[1] and optional glucose alarms directly to smartphones[2] for people ...
Forbes

2 Million Patients And Beyond: Abbott’s FreeStyle Libre 2 Cleared In The U.S. For Adults And Children With Diabetes

Pharmaceutical and med device giant Abbott (NYSE: ABT) said today that it had received approval from the Food and Drug Administration (FDA) for its next-generation integrated continuous glucose ...